In Vitro Effect of Soy Isoflavone and Equol on Soluble CD40L Release Stimulated by Ristocetin in Platelets from Postmenopause Women
Read full paper at:
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=53275#.VLxqX8nQrzE
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=53275#.VLxqX8nQrzE
ABSTRACT
The inhibition of specific flavonoid on the in vitro
platelet aggregation induced by collagen, arachidonic acid and
thromboxane A2 (TxA2) agonist, seems to be related mostly to their
ability to compete for binding to the TxA2 receptor (TP). The aim of
this study was to analyze the effect of soy isoflavone and equol in
terms of inhibiting the platelet aggregation and sCD40L release
stimulated by ristocetin, an in vitro-activator of glycoprotein
Ib/IX/V, in platelets from postmenopausal women. When platelets were
stimulated by 0.75 mg/ml ristocetin, equol (10 μM) exhibited a greater
inhibitory activity on platelet aggregation (~68%) than genistein or
daidzein. The effect of equol was dependent on the concentration of
platelet aggregation agonist. In the presence of ristocetin (0.75 mg/ml,
1.125 mg/ml and 1.5 mg/ml), the inhibitory effect of 10 μM equol was
68% ± 5%, 54% ± 4% and 31% ± 5%, respectively. Equol (10 μM) was a
potent inhibitor (~35%) of sCD40L release when stimulated with 1.5 mg/ml
ristocetin. However, no significant differences were noted in platelets
incubated in the presence of genistein or daidzein and stimulated by
ristocetin. On the other hand, SQ29548, a high TP antagonist, also
inhibited the sCD40L release stimulated by ristocetin. Finally, 10 μM of
genistein, daidzein or equol did not significantly affect the
thromboxane B2 production when platelets were incubated with 1.5 mg/ml
ristocetin. The relevance of this study was to find that equol exhibits a
potent activity by inhibiting ristocetin-induced sCD40L release,
suggesting that soy isoflavone has important biological effects on the
hemostatic system. However, clinical trials will be necessary to assess
the effect of equol on platelet and their impact on inflammatory
markers.
Cite this paper
References
Gonzalez, N. , Garrido, A. , Acevedo, I. and Valladares, L. (2015) In Vitro Effect of Soy Isoflavone and Equol on Soluble CD40L Release Stimulated by Ristocetin in Platelets from Postmenopause Women. Journal of Biomedical Science and Engineering, 8, 24-30. doi: 10.4236/jbise.2015.81002.
| [1] | Setchell, K.D. and Cassidy, A. (1990) Dietary Isoflavones: Biological Effects and Relevance to Human Health. Journal of Nutrition, 129, 758S-767S. |
| [2] | Jackson,
R.L., Greiwe, J.S. and Schwen, R.J. (2011) Emerging Evidence of the
Health Benefits of S-Equol, an Estrogen Receptor β Agonist. Nutrition
Review, 69, 432-448. http://dx.doi.org/10.1111/j.1753-4887.2011.00400.x |
| [3] | Cano, A., García-Pérez, M.A. and Tarín, J.J. (2010) Isoflavones and Cardiovascular Disease. Maturitas, 67, 219-226. http://dx.doi.org/10.1016/j.maturitas.2010.07.015 |
| [4] | Siow,
R.C. and Mann, G.E. (2010) Dietary Isoflavones and Vascular Protection:
Activation of Cellular Antioxidant Defenses by SERMs or Hormesis?
Molecular Aspects of Medicine, 31, 468-477. http://dx.doi.org/10.1016/j.mam.2010.09.003 |
| [5] | Li,
Z., Delaney, M.K., O’Brien, K.A. and Du, X. (2010) Signaling during
Platelet Adhesion and Activation. Arteriosclerosis, Thrombosis, and
Vascular Biology, 30, 2341-2349. http://dx.doi.org/10.1161/ATVBAHA.110.207522 |
| [6] | Gawaz,
M., Langer, H. and May, A.E. (2005) Platelets in Inflammation and
Atherogenesis. The Journal of Clinical Investigation, 115, 3378-3384. http://dx.doi.org/10.1172/JCI27196 |
| [7] | Nurden, A.T. (2011) Platelets, Inflammation and Tissue Regeneration. Thrombosis and Haemostasis, 105, S13-S33. http://dx.doi.org/10.1160/THS10-11-0720 |
| [8] | Dong,
J.F., Berndt, M.C., Schade, A., McIntire, L.V., Andrews, R.K. and
López, J.A. (2001) Ristocetin-Dependent, but Not Botrocetin-Dependent,
Binding of von Willebrand Factor to the Platelet Glycoprotein Ib-IX-V
Complex Correlates with Shear-Dependent Interactions. Blood, 97,162-168.
http://dx.doi.org/10.1182/blood.V97.1.162 |
| [9] | Enomoto,
Y., Adachi, S., Matsushima-Nishiwaki, R., Doi, T., Niwa, M., Akamatsu,
S., Tokuda, H., Ogura, S., Yoshimura, S., Iwama, T. and Kozawa, O.
(2010) Thromboxane A2 Promotes Soluble CD40 Ligand Release from Human
Platelets. Atherosclerosis, 209, 415-421. http://dx.doi.org/10.1016/j.atherosclerosis.2009.10.024 |
| [10] | Munoz,
Y., Garrido, A. and Valladares, L. (2009) Equol Is More Active than Soy
Isoflavone Itself to Compete for Binding to Thromboxane A(2) Receptor
in Human Platelets. Thrombosis Research, 123, 740-774. http://dx.doi.org/10.1016/j.thromres.2008.07.011 |
| [11] | Guerrero,
J.A., Lozano, M.L., Castillo, J., Benavente-Garcia, O., Vicente, V. and
Rivera, J. (2005) Flavonoids Inhibit Platelet Function through Binding
to the Thromboxane A2 Receptor. The Journal of Thrombosis and
Haemostasis, 3, 369-376. http://dx.doi.org/10.1111/j.1538-7836.2004.01099.x |
| [12] | Garrido, A., Munoz, Y., Sierralta, W. and Valladares, L. (2012) Metabolism of Dehydroepiandrosterone Sulfate and Estrone- Sulfate by Human Platelets. Physiological Research, 61, 381-388. |
| [13] | Schonbeck, U. and Libby, P. (2001) The CD40/CD154 Receptor/Ligand Dyad. Cellular and Molecular Life Sciences, 58, 4-43. http://dx.doi.org/10.1007/PL00000776 |
| [14] | Lievens,
D., Zernecke, A., Seijkens, T., Soehnlein, O., Beckers, L., Munnix,
I.C., Wijnands, E., Goossens, P., van Kruchten, R., Thevissen, L., Boon,
L., Flavell, R.A., Noelle, R.J., Gerdes, N., Biessen, E.A., Daemen,
M.J., Heemskerk, J.W., Weber, C. and Lutgens, E. (2010) Platelet CD40L
Mediates Thrombotic and Inflammatory Processes in Atherosclerosis.
Blood, 116, 4317-4327. http://dx.doi.org/10.1182/blood-2010-01-261206 |
| [15] | Derosa,
G., D’Angelo, A., Mugellini, A., Pesce, R.M., Fogari, E. and Maffioli,
P. (2012) Evaluation of Emerging Biomarkers in Cardiovascular Risk
Stratification of Hypertensive Patients: A 2-Year Study. Current Medical
Research and Opinion, 28, 1435-1445. http://dx.doi.org/10.1185/03007995.2012.717527 |
| [16] | Halushka,
P.V., Mais, D.E., Mayeux, P.R. and Morinelli, T.A. (1989) Thromboxane,
Prostaglandin and Leukotriene Receptors. Annual Review of Pharmacology
and Toxicology, 29, 213-239. http://dx.doi.org/10.1146/annurev.pa.29.040189.001241 |
| [17] | Giannarelli,
C., Zafar, M.U. and Badimon, J.J. (2010) Prostanoid and TP-Receptors in
Atherothrombosis: Is There a Role for Their Antagonism? Thrombosis and
Haemostasis, 104, 949-954. http://dx.doi.org/10.1160/TH10-03-0195 |
| [18] | Ostertag,
L.M., O’Kennedy, N., Kroon, P.A., Duthie, G.G. and de Roos, B. (2010)
Impact of Dietary Polyphenols on Human Platelet Function—A Critical
Review of Controlled Dietary Intervention Studies. Molecular Nutrition
& Food Research, 54, 60-81. http://dx.doi.org/10.1002/mnfr.200900172 |
| [19] | Navarro-Núnez,
L., Castillo, J., Lozano, M.L., Martínez, C., Benavente-García, O.,
Vicente, V. and Rivera, J. (2009) Thromboxane A2 Receptor Antagonism by
Flavonoids: Structure-Activity Relationships. Journal of Agricultural
and Food Chemistry, 57, 1589-1594. http://dx.doi.org/10.1021/jf803041k |
| [20] | Sacks,
F.M., Lichtenstein, A., Van Horn, L., Harris, W., Kris-Etherton, P. and
Winston, M. (2006) Soy Protein, Isoflavones, and Cardiovascular Health:
A Summary of a Statement for Professionals from the American Heart
Association Nutrition Committee. Arteriosclerosis, Thrombosis, and
Vascular Biology, 26, 1689-1692. http://dx.doi.org/10.1161/01.ATV.0000227471.00284.ef |
| [21] | Xiao, C.W. (2008) Health Effects of Soy Protein and Isoflavones in Humans. Journal of Nutrition, 138, 12445-12495. |
| [22] | Zubik, L. and Meydani, M. (2003) Bioavailability of Soybean Isoflavones from Aglycone and Glucoside Forms in American Women. The American Journal of Clinical Nutrition, 77, 1459-1465. |
| [23] | Bolca,
S., Urpi-Sarda, M., Blondeel, P., Roche, N., Vanhaecke, L., Possemiers,
S., Al-Maharik, N., Botting, N., De Keukeleire, D., Bracke, M.,
Heyerick, A., Manach, C. and Depypere, H. (2010) Disposition of Soy
Isoflavones in Normal Human Breast Tissue. The American Journal of
Clinical Nutrition, 91, 976-984. http://dx.doi.org/10.3945/ajcn.2009.28854 |
| [24] | Larkin,
T., Price, W.E. and Astheimer, L. (2008) The Key Importance of Soy
Isoflavone Bioavailability to Understanding Health Benefits. Critical
Reviews in Food Science and Nutrition, 48, 538-552. http://dx.doi.org/10.1080/10408390701542716 eww150119lx |
评论
发表评论